Downloadable ContentDownload PDF
Assessing Global Cooperation as a Force for Health 2013 to 2018: Quantifying Interaction Among Select Portuguese and Non-Portuguese Speaking Countries in Dealings with Access to First-Line Medications, and Possible Impacts of SARS-CoV-2 on Access to Medical Services
Human Immunodeficiency Virus (HIV) and Malaria are two diseases which place a significant socioeconomic burden on developing Portuguese-speaking African nations and other Sub-Saharan African nations. These diseases require the coordination of global efforts to be addressed in order to deliver funding and pharmaceuticals. However, with the emergence of the SARS-CoV-2 (COVID-19) virus the global community has been challenged to adapt and respond to this novel virus while maintaining the disease control programs dedicated to HIV and malaria. Our aim to assess the potential for impact of the emergence of SARS-CoV-2 on pharmaceutical flow and funding for control programs of other diseases of global health importance, specifically HIV and malaria. We will examine the number of HIV and malaria cases, deaths, and medications delivered between the years of 2013 to 2018, among two cohorts of three countries each. The comparison will illuminate any differences in health outcomes due to fluctuations in funding and pharmaceuticals geared toward the treatment of HIV and malaria. With this information, we will discuss the potential impacts to disease control efforts due to COVID-19 disruptions and provide recommendations to help mitigate the effects of the pandemic on other health programs.